Genetic testing is moving from targeted investigations of monogenetic diseases to broader testing that may provide more information. For example, recent health economic studies of genetic testing for an increased risk of breast cancer suggest that it is associated with higher cost-effectiveness to ...
“The more I can normalize genetic testing, the more lives we can save,” she said.At age 19, Kinsey tested positive for the BRCA1 gene mutation. A BRCA (breast cancer) gene mutation increases a person’s risk for developing several types of cancer, primarily breast cancer and ovarian ...
Most women know about mammograms for early detection of breast cancer. The BRCA1 and BRCA2 genetic tests are much less widely known. Dr. Douglas E.
3 ⅐ No. 2 Genetic testing for breast cancer: Where are health care providers in the decision process? Christine M. Velicer, MS1,2, and Stephen Taplin, MD, MPH2,3 Purpose: To identify BRCA1/2 knowledge, genetic testing intentions, and communication patterns in breast cancer survivors (...
"Women with a family history of breast cancer are being referred to labs for genetic testing, and mutations are being identified, but if you can't translate a result into a fairly precise breast cancer risk, it can lead to improper risk management advice. We wanted to help clinics interpret...
Targeted genetic testing is a tool to identify women at increased risk of gynaecological cancer.Objective: This systematic review evaluates the results and quality of cost-effectiveness modeling studies that assessedtargeted genetic-based screen-and-treat strategies to prevent breast and ovarian cancer.Met...
To examine the relative cost-effectiveness of predictive genetic tests for familial breast and ovarian cancer provided by Genetic Services of Western Australia. The relative cost-effectiveness was assessed using a decision analytic model. The cost and outcomes of genetic testing was compared in first-...
Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population Young women from hereditary breast and ovarian cancer (HBOC) families face a unique set of challenges in managing their HBOC risk, where obtaining essen...
chemotherapy costs of $2.701 billion and Oncotype DX testing costs estimated to be $115 million, for a total healthcare cost of $2.816 billion in the first year after diagnosis. The researchers estimated that only 34.8 to 57.2 percent of women were receiving the Oncotype DX testing in this pe...
Recently, genetic testing has begun to move from the customary clinical setting (with restrictive entry criteria) into the offices of GPs and the homes of consumers (Williams-Jones, 2003). This research aimed to look at participants' experiences of genetic testing for hereditary breast and ovarian...